Gasoheal-DSR Capsule is a combination pharmaceutical formulation containing Domperidone 30mg and Rabeprazole 20mg, designed to manage gastrointestinal disorders characterized by acid-related symptoms and motility disturbances. Domperidone, a peripheral dopamine D2 receptor antagonist, enhances gastrointestinal motility by promoting gastric emptying and improving esophageal sphincter tone, thereby alleviating symptoms such as nausea, vomiting, bloating, and dyspepsia. Rabeprazole, a proton pump inhibitor (PPI), suppresses gastric acid secretion by irreversibly inhibiting the H+/K+ ATPase enzyme system at the secretory surface of gastric parietal cells, effectively reducing gastric acidity and providing symptomatic relief in conditions like gastroesophageal reflux disease (GERD), peptic ulcers, and erosive esophagitis. The synergistic action of these agents in Gasoheal-DSR Capsule addresses both the hyperacidity and delayed gastric emptying components of gastrointestinal disorders, offering comprehensive symptom control. This combination is indicated for the treatment of GERD, functional dyspepsia, and other acid-peptic diseases where delayed gastric emptying contributes to symptomatology. Gasoheal-DSR Capsule should be administered as prescribed by a healthcare professional, with caution advised in patients with known hypersensitivity to either component, underlying cardiac conditions, or hepatic impairment. Regular monitoring and adherence to recommended dosages are essential to minimize potential adverse effects and ensure therapeutic efficacy.